“TULIP-2 was a positive phase 3 trial in lupus, and there haven’t been many times before that those words have been spoken” - @EricFMorand Anifrolumab in mod-severe SLE #ACR19 L17 @RheumNow @US_FDA https://t.co/8lqBmaWHW0